Immunome IMNM 深 沪
已收盘 08-21 16:00:00 美东时间
28.52
+0.440
+1.57%
华盛通- 最 高29.30
- 今 开28.46
- 成交量 84.88万股
- 最 低 28.125
- 昨 收 28.08
- 总市值 32.39亿
- 52周最高 30.06
- 市盈率 静 --
- 换手率 0.75%
- 52周最低 8.665
- 委 比 1.96%
- 总股本 1.14亿
- 历史最高 63.78
- 量 比 0.61
- 振 幅 4.18%
- 历史最低 2.09
- 每 手 1
- 风险率 4.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
Wedbush Maintains Outperform on Immunome, Raises Price Target to $35
Wedbush analyst David Nierengarten maintains Immunome (NASDAQ:IMNM) with a Outperform and raises the price target from $31 to $35.
08-13 00:09
Immunome Q2 EPS $(0.65) Misses $(0.52) Estimate
Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.52) by 25 percent. This is a 30 percent decrease over losses of $(0.50) per share from the same period last year.
08-12 04:34
Gilead Sciences Inc Stock (GILD) Moved Down by 3.96% on Aug 5: A Full Analysis
• Gilead Sciences shares fell after lowering its full-year earnings guidance. • Decelerating HIV franchise sales and lackluster oncology clinical results impacted investor sentiment. • Increased operational and research costs compressed the company's profit margins.
08-05 16:15
美股大行评级 | 富国银行上调亚马逊目标价从313美元升至322美元；潜在涨幅370.99%！HC Wainwright上调Greenwich LifeSciences目标价至69美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Greenwich LifeSciences"买入"评级，目标价从50美元升至69美元；高盛：维持Taysha Gene Therapies"买入"评级，目标价从11美元升至13美元
07-22 11:35
Wedbush Reiterates Outperform on Immunome, Maintains $31 Price Target
Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and maintains $31 price target.
07-21 21:33
Immunome启动IM-3050放射性配体疗法Ⅰ期临床试验 首例患者完成给药
生物制药公司Immunome周一宣布，其研发的FAP靶向放射性配体疗法IM-3050在针对表达FAP的晚期实体瘤患者的Ⅰ期临床试验中已完成首例患者给药。这标...
07-20 21:57
Immunome Clears Key Regulatory Milestone as Lead Drug Goes Under FDA Review
Immunome Inc. (NASDAQ:IMNM) said the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application for varegacestat, an investigational oral, once-daily gamma secretase inhibitor, for the treatment of adults with desmoid tumors. The agency assigned a Prescription Drug User Fee Act ta...
07-09 01:18
Immunome granted FDA review for tumor candidate
Immunome (IMNM) announced on Wednesday that the U.S. FDA has accepted its marketing application for its lead asset, varegacestat, targeted at a group of noncancerous soft tissue lesions known as desmo...
07-08 21:52
